Molecular profiling: moving away from tumor philately

JS Reis-Filho, B Weigelt, D Fumagalli… - Science translational …, 2010 - science.org
Despite the remarkable enhancements in breast cancer classification and characterization,
an exhaustive comprehension of the underlying carcinogenic processes and an accurate …

Advances in the proteomic discovery of novel therapeutic targets in cancer

S Guo, J Zou, G Wang - Drug design, development and therapy, 2013 - Taylor & Francis
Proteomic approaches are continuing to make headways in cancer research by helping to
elucidate complex signaling networks that underlie tumorigenesis and disease progression …

Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry

S Zanivan, F Gnad, SA Wickström… - Journal of proteome …, 2008 - ACS Publications
Kinases play a prominent role in tumor development, pointing to the presence of specific
phosphorylation patterns in tumor tissues. Here, we investigate whether recently developed …

[HTML][HTML] Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner

N Dey, B Young, M Abramovitz, M Bouzyk, B Barwick… - PloS one, 2013 - journals.plos.org
Mutations of genes in tumor cells of Triple Negative subset of Breast Cancer (TNBC)
deregulate pathways of signal transduction. The loss of tumor suppressor gene PTEN is the …

Quantified tumor T1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability

PMJ McSheehy, C Weidensteiner, C Cannet… - Clinical Cancer …, 2010 - AACR
Purpose: Identification of a generic response biomarker by comparison of
chemotherapeutics with different action mechanisms on several noninvasive biomarkers in …

[HTML][HTML] Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model

DK Rhee, SH Park, YK Jang - Genomics, 2008 - Elsevier
Comparative microarray analyses provided insight into understanding transcript changes
during cancer progression; however, a reproducible signature underlying breast …

Tumor marker phenotype concordance in second primary breast cancer, California, 1999–2004

M Brown, K Bauer, M Pare - Breast cancer research and treatment, 2010 - Springer
Breast cancer is the most common cancer among women. It is estimated that 7% of women
who have breast cancer will develop a subsequent second independent breast tumor within …

Biotechnology and bioinformatics: Advances and applications for bioenergy, bioremediation and biopharmaceutical research

D Thangadurai, J Sangeetha - 2014 - books.google.com
Reflecting the interdisciplinary nature of biotechnology, this book covers the role of targeted
delivery of polymeric nanodrugs to cancer cells, microbial detoxifying enzymes in …

[HTML][HTML] Recommendations for research priorities in breast cancer by the Coalition of Cancer Cooperative Groups Scientific Leadership Council: systemic therapy and …

JA Sparano, GN Hortobagyi, JR Gralow… - Breast cancer research …, 2010 - Springer
Over 9,000 women with breast cancer are enrolled annually on clinical trials sponsored by
the National Cancer Institute (NCI), accounting for about one-third of all patients enrolled on …

Insights into apoptotic proteins in chemotherapy: quantification techniques and informing therapy choice

J Naß, T Efferth - Expert Review of Proteomics, 2018 - Taylor & Francis
Introduction: Cancer is one of the leading causes of morbidity and mortality worldwide. A
hallmark of cancer is evasion of apoptosis leading to tumor progression and drug resistance …